

May 15, 2007



Merial-SCYNEXIS Research Collaboration Expanded

DULUTH, GA, and RESEARCH TRIANGLE PARK, NC -- (MARKET WIRE) -- 05/15/07 -- Merial Limited and SCYNEXIS, Inc. announced today that they have expanded the scope of their research collaboration as a result of the success of their first agreement which began in 2005. SCYNEXIS, a primary drug discovery and development company and collaborator with Merial, will, under the terms of a new multi-year agreement, significantly increase the capacity of their technologically advanced biological screening, bioanalytical, ADMET and medicinal chemistry efforts directed towards Merial projects.

"Merial is very pleased to collaborate with SCYNEXIS to further expand our ability to identify and optimize novel active compounds that will form the basis of new products designed to meet our customers' future needs," states Dr. Kevin Schultz, Chief Scientific Officer and Head of Global R&D.

"Innovation-driven companies such as Merial are constantly exploring new products that will meet the demands of the growing animal health market. Collaborating with drug discovery and development companies such as SCYNEXIS can offer novel opportunities to provide new pharmaceuticals to a wide range of companion and production animal species. This new collaboration will allow for faster delivery of novel drugs to Merial that will further impact this dynamic market," said SCYNEXIS President and CEO Dr. Yves Ribeill.

About Merial

Merial is a world-leading, innovation-driven animal health company, providing a comprehensive range of products to enhance the health, well-being and performance of a wide range of animals. Merial employs approximately 5,000 people and operates in more than 150 countries worldwide. Its 2006 sales were nearly \$2.2 billion. Merial Limited is a joint venture between Merck & Co., Inc. and sanofi-aventis. For more information, please see www.merial.com.

About SCYNEXIS

SCYNEXIS is a premier drug discovery and development company headquartered in Research Triangle Park, North Carolina. Our mission is to be the leader in delivering effective and innovative drug pipeline solutions to our pharmaceutical partners.

SCYNEXIS research teams integrate medicinal chemistry, biological screening, computational chemistry, bioanalysis and analytical chemistry which use powerful, proprietary technologies such as the HEOS® Software Suite, MEDCHEM-FACTORY® and KIT(TM) Kinase Inhibitor Technology to advance molecules to candidate selection. We have tailored our development teams to be especially effective in moving customer projects from the discovery phase to the clinic. Our process chemistry and bioanalytical departments

operate under current GMP/GLP guidelines and have a strong track record of success. Our website is located at www.scynexis.com

®HEOS and MEDCHEM-FACTORY are registered trademarks of SCYNEXIS, Inc. and (TM)KIT Kinase Inhibitor Technology is a trademark of SCYNEXIS, Inc.

Contact:

Kelle Straw

Merial

678-638-3690

[Email Contact](#)

Rick Rountree

SCYNEXIS

919-878-1144

[Email Contact](#)